Literature DB >> 19237188

MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.

Todd Boren1, Yin Xiong, Ardeshir Hakam, Robert Wenham, Sachin Apte, Gina Chan, Siddharth G Kamath, Dung-Tsa Chen, Holly Dressman, Johnathan M Lancaster.   

Abstract

OBJECTIVE: Few successful therapeutic options exist for patients with recurrent ovarian cancer (OVCA). This is due in part to an incomplete understanding of the molecular determinants of chemotherapy-response. Recently, it has been shown that microRNAs (miRNAs) influence messenger-RNA (mRNA) post-transcriptional control and can contribute to human carcinogenesis. The objective of the current study was to explore the role of miRNAs, and their predicted mRNA targets, in OVCA in-vitro response to chemotherapy.
METHODS: The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses.
RESULTS: Twenty-seven miRNAs were found to be associated with response to the one or more of the 6 salvage chemotherapies tested (p<0.05). Predicted targets of these miRNAs included 52 mRNAs, previously reported to be associated with chemo-responsiveness, and which are also involved in functional biologic pathways that influence cancer cell cytotoxicity, carcinogenesis, cell mitosis, p53 signaling, and tumor cell growth and invasion.
CONCLUSION: We have identified miRNAs and their predicted target mRNAs associated with ovarian cancer cell response to chemotherapeutic agents. Our strategy of integrating miRNA and mRNA data may aid in the characterization of important molecular pathways associated with OVCA chemo-response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237188     DOI: 10.1016/j.ygyno.2009.01.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  65 in total

1.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

2.  Matrix metalloproteinase 9 expression: new regulatory elements.

Authors:  Irina Surgucheva; Kumaravel Chidambaram; David A Willoughby; Andrei Surguchov
Journal:  J Ocul Biol Dis Infor       Date:  2010-08-05

3.  Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells.

Authors:  Dhwanil Damania; Hemant K Roy; Dhananja Kunte; Jean A Hurteau; Hariharan Subramanian; Lusik Cherkezyan; Nela Krosnjar; Maitri Shah; Vadim Backman
Journal:  Int J Cancer       Date:  2013-04-01       Impact factor: 7.396

4.  Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.

Authors:  Ling Liu; Jing Zou; Qi Wang; Fu-Qiang Yin; Wei Zhang; Li Li
Journal:  Tumour Biol       Date:  2014-05-08

5.  MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.

Authors:  Jing Xie; Fei Yu; Dan Li; Xuchao Zhu; Xiaoping Zhang; Zhongwei Lv
Journal:  Tumour Biol       Date:  2015-08-18

Review 6.  Non-coding RNA in Ovarian Development and Disease.

Authors:  J Browning Fitzgerald; Jitu George; Lane K Christenson
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

8.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

9.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

10.  Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer.

Authors:  Parag P Shah; Lauren E Hutchinson; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-08-27       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.